Table 3 Concept prevalence concepts missing from the OMOP2OBO mapping set.

From: Ontologizing health systems data at scale: making translational discovery a reality

OMOP domain

Concept

Concept labela

Average concept frequencyb

Study sites

Condition

4,091,502

Increased fluid intake

100,483.0

1

 

37,311,061

COVID-19

93,585.0

1

 

40,443,308

Polycystic ovary syndrome

62,900.3

3

 

35,615,055

Saddle embolus of pulmonary artery with acute cor pulmonale

22,324.4

10

 

36,684,319

Adjustment disorder with mixed anxiety and depressed mood

18,453.0

1

Drug Ingredient

37,498,625

Hepatitis A virus strain CR 326F antigen, inactivated

175,551.3

14

 

1,510,467

Erenumab

60,618.0

10

 

35,200,577

Fremanezumab

15,579.6

5

 

35,200,800

Galcanezumab

11,594.8

5

 

35,201,105

Baloxavir marboxil

11,366.7

3

Measurement

3,045,980

Pulse intensity of Unspecified artery palpation

1,219,846,862.0

1

 

3,021,716

Penicillin G potassium [Mass] of Dose

253,609,945.0

1

 

40,760,098

Sodium [Moles/volume] in Saliva (oral fluid)

246,641,311.0

1

 

3,045,820

Cotinine/Creatinine [Mass Ratio] in Urine

246,063,202.0

1

 

3,008,500

Chloride [Moles/volume] in Saliva (oral fluid)

234,931,483.0

1

  1. OMOP Observational Medical Outcomes Partnership.
  2. aConcept labels were obtained from the Athena web application (https://athena.ohdsi.org/) on 12/29/2022.
  3. bThe average concept frequency was calculated as the frequency of each concept divided by the number of Concept Prevalence study sites with that concept by each clinical domain.